Technology News, Search Engine

Technology News & Search Engine

Technology News and Search Engine - Computers and Software,
Internet, Personal and Enterprise Technogy News. Website Builder.
Press release distribution service
Home | Technology News Search Engine:                                     

Home: Technology News:

Mesenchymal Stem Cells - Advances & Applications Forecast Report Available Online by


(IT-NEWSWIRE.COM, July 28, 2015 )
Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells. MSCs are of intense therapeutic interest because they represent a population of cells with the potential to treat a wide range of acute and degenerative diseases.

Read The Complete Report With TOC @

MSCs are advantageous over other stem cells types for a variety of reasons: they avoid the ethical issues that surround embryonic stem cell research, and repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogenic transplantation. MSCs reduce both the risks of rejection and complications of transplantation. Recently, there have been advances in the use of autologous Mesenchymal stem cells to regenerate human tissues, including cartilage, meniscus, tendons, bone fractures, and more.

This global strategic report explores recent advances in MSC research applications, research priorities by market segment, and the competitive environment for MSC research products. It also identifies trend and growth patterns within the MSC industry. Because it is important for pharmaceutical companies interested to understand underlying forces affecting the MSC market, this report also presents a range of topics that apply to these companies, including how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.

Literature and data concerning the biology and differentiation potential of mesenchymal stem cells (MSCs) has expanded rapidly over the past 10 years, with more than 13,000 publications now exploring aspects of MSC biology, behavior, and applications. In particular, MSCs appear to be an exceptionally promising tool for cell therapy because of their unusual characteristics, which partially mimic those of embryonic stem cells, while having advantages in terms of availability, expandability, transplantability, and ethical implications.

Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as from their ability to migrate to sites of tissue injury/inflammation or tumor growth. These localization properties present a promising strategy for targeted introduction of therapeutic agents through MSC gene therapy. In addition, MSCs possess strong immunosuppressive properties that medical researchers are exploiting for both autologous as well as heterologous therapies.

Clinical Progress with MSCs

As mentioned, mesenchymal stem cells (MSCs) have inspired a lot of activity over the past ten years as a novel therapeutic model for a wide range of diseases. Presently, MSCs-based clinical trials are being conducted for twelve types of disease conditions, with many completed trials showing their safety and efficacy.

Request A Report Sample @

The clinical utility of MSCs are mostly attributed to their four key biological properties, which are their potential to:

Migrate to sites of inflammation caused by tissue injury when injected intravenously
To get differentiated into different cell types
To release different bioactive molecules having the potential of stimulating recovery of injured cells and preventing inflammation
To accomplish immunomodulatory functions

Currently, there are 128 clinical trials involving MSCs are in progress in different parts of the world, including China, the European Union, the United States, the Middle East, and South Korea. Among these trials, 45 (35%) are exploiting MSCs for various disease indications. Currently, four major clinical trials using MSCs have reached Phase III. Stempeutics Research’s product candidate Stempeucel is being evaluated in two centers for treating critical leg ischemia. Prochymal is the product candidate from Osiris Therapeutics and it is being used for treating graft vs. host disease (GvHD). The company is also testing Prochymal for treating Crohn’s disease in another Phase III trial. The Australian company Mesoblast is testing an ‘off-the-shelf’ mesenchymal precursor product candidate for treating patients with hematological malignancies.


This global strategic report is produced for:

Management of stem cell companies
Management of regenerative therapy companies
Stem cell industry investors

It is designed to increase your efficiency and effectiveness in:

Commercializing mesenchymal stem cell (MSC) products, technologies, and therapies
Making intelligent investment decisions
Launching high-demand products
Selling effectively to your client base
Increasing revenue from MSC products and services
Taking market share from your competition

Since 1968, bone marrow transplantation (BMT) has been the gold standard treatment for blood cancer patients and others with genetic blood disorders. Each year more than 60,000 bone marrow transplantations are performed worldwide, and 58% of these procedures use autologous bone marrow and 42% of the cases use allogeneic bone marrow. Currently, the use of bone marrow is being replaced by the utilization of MSCs for some conditions.

The majority of cell therapy products currently being marketed are meant to address musculoskeletal conditions, and most of these products use MSCs as a component.

All Countrywise Report @

Report Objectives

The purpose of this report is to describe the current status of mesenchymal stem cells (MSCs) research, the ongoing clinical trials involving MSCs, late stage MSCs clinical trials, and the possible uses of MSCs in cell therapy. As MSC cell therapy is an integrated component of other cell therapies and regenerative medicines (RM), the report also gives a brief overview of the RM industry and overall cell therapy (CT) industry.

Thus, the main objectives are to consider the following:

Current status of global regenerative medicine (RM) industry in the utilization of stem cells in general and MSCs in particular.
Current status of global cell therapy (CT) industry, the application of cell therapy in various disease indications, and the total number of clinical trials involving the different types of stem cells.
Current status of MSCs in clinical trials, the dominance of MSCs in the ongoing clinical trials involving stem cells, the various applications of MSCs in different disease indications, and the number of clinical trials involving MSCs for different disease types.
The number of companies involved in the development of MSCs, the clinical trials sponsored by major companies, and their sustained search for MSCs-based cell therapy products.

For More Information Kindly Contact:
Mr. Nachiket Ghumare, +1-518-621-2074
USA-Canada Toll Free: 866-997-4948

Researchmoz Global Pvt.Ltd



Source: EmailWire.Com


Sponsored Links

EmailWire Business Directory
EmailWire Business Directory about Legal, Stocks, Investment, Markets, Stocks

Submit website to Business Directory

Listen to GroupWeb Radio

Technology News Headlines
  • Computer Security
  • Digital Music
  • Digital Video/TV
  • Enterprise
  • Linux/Open Source
  • Microsoft
  • Mobil Phones
  • Internet
  • Personal Technology
  • Portals & Search Engines
  • RSS and Blogging
  • Software
  • Technology News
  • GroupWeb Market Place
    Website Builder - Blog Builder
    Build your website in 5 minutes. One month free. No setup fee! Blog Included.

    Your text Ads here!
    Ads are only $50 per month.Please contac us and state ou want to place advertisement on

    Technology Business Video Feed

    More Technology Video Feeds
  • Computers
  • Computers & Software
  • Home Theater
  • Personal Technology
  • TechBiz
  • TechBytes
  • Technology Publications

    We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including:

    Search Engine Optimization for E-commerce Sites: The Seven Most Common Pitfalls
    Website Magazine
    Business Activity Monitoring: Smart Decisions with Real-time Visibility

    No credit cards, coupons, or promo codes required. Try it today!

    Press release distribution service

    :: Home: :: Submit Press Release :: Subscribe to News :: Contact Us :: Help

    For unlimited press release distribution for $59 per month, call (281) 645-4086 or start posting your press releases online at
    Copyright 2008 GroupWeb Media LLC
    GroupWeb Media Network

    Aviation-NewsWire | ArtNewsWire | Auction NewsWire | CRM NewsWire | ePhotoNewsWire | Energy Industry | EstateNewsWire | | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | i-Homeland Security.Com | iMac-NewsWire.Com | i-Press-Release-Service | | iT-NewsWire.Com
    | i-TravelNewsWire.Com | MoneyNewsWire.Net | Movie-Stars-News.Com | MSNewsWire.Net | PharmaNewsWire.Com | Publishing-NewsWire.Com | RSSNewsWire.Net | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com | VoIPNewsWire.Net | XSportsWorld.Net - a Technology News and Resource of GroupWeb Media LLC